Abstract
The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 microgram were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 microgram were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.
MeSH Terms
Animals
Antibodies, Bacterial/biosynthesis
Antigens, Bacterial/analysis,immunology
Bacterial Vaccines/immunology,standards,toxicity
Guinea Pigs
Horseshoe Crabs/immunology
Humans
Molecular Weight
Opsonin Proteins/immunology
Polysaccharides, Bacterial/immunology,standards
Pseudomonas aeruginosa/immunology
Serotyping
Chemicals
Antibodies, Bacterial
Antigens, Bacterial
Bacterial Vaccines
Opsonin Proteins
Polysaccharides, Bacterial
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Pier G B
References (17)
17 references, click to expand
-
Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.
Lancet. 1980 Dec 13;2(8207):1263-5
PMID: 6108445
-
Correlation of the biologic responses of C3H/HEJ mice to endotoxin with the chemical and structural properties of the lipopolysaccharides from Pseudomonas aeruginosa and Escherichia coli.
J Immunol. 1981 Jul;127(1):184-91
PMID: 6787121
-
Advances in the management of Pseudomonas aeruginosa infections in cancer patients.
Eur J Cancer. 1973 Jun;9(6):435-41
PMID: 4372050
-
Type-specific immunity in pseudomonas diseases.
J Lab Clin Med. 1972 Jan;79(1):47-54
PMID: 4621414
-
Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa.
Infect Immun. 1978 Dec;22(3):919-25
PMID: 103841
-
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.
J Clin Invest. 1979 Feb;63(2):276-86
PMID: 429553
-
Pseudomonas bacteremia. Review of 108 cases.
Am J Med. 1976 Apr;60(4):501-8
PMID: 818897
-
A new polyvalent Pseudomonas vaccine.
J Med Microbiol. 1977 Feb;10(1):19-27
PMID: 402473
-
Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides.
J Infect Dis. 1972 Sep;126(3):277-87
PMID: 4626510
-
Immunization against Pseudomonas in infection after thermal injury.
J Infect Dis. 1974 Nov;130 Suppl(0):S152-8
PMID: 4138646
-
Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.
J Infect Dis. 1972 Sep;126(3):257-76
PMID: 4626509
-
Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa.
Infect Immun. 1978 Dec;22(3):908-18
PMID: 103840
-
Agar-Gel Precipitating Antibody in Pseudomonas aeruginosa Infections.
Infect Immun. 1970 Oct;2(4):495-503
PMID: 16557868
-
Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies.
Ann Intern Med. 1975 Jun;82(6):819-31
PMID: 806246
-
High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2.
Infect Immun. 1981 Nov;34(2):461-8
PMID: 6171520
-
Pseudomonas aeruginosa vaccine in cancer patients.
Ann Intern Med. 1973 Oct;79(4):518-27
PMID: 4201225
-
Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis.
Am J Med. 1975 May;58(5):629-36
PMID: 805535